BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 25967739)

  • 1. Thioimidazoline based compounds reverse glucocorticoid resistance in human acute lymphoblastic leukemia xenografts.
    Toscan CE; Rahimi M; Bhadbhade M; Pickford R; McAlpine SR; Lock RB
    Org Biomol Chem; 2015 Jun; 13(22):6299-312. PubMed ID: 25967739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-throughput screening of human leukemia xenografts to identify dexamethasone sensitizers.
    Toscan CE; Failes T; Arndt GM; Lock RB
    J Biomol Screen; 2014 Dec; 19(10):1391-401. PubMed ID: 25104793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib Treatment can Overcome Glucocorticoid Resistance in Childhood B-cell Precursor Acute Lymphoblastic Leukemia Cell Lines.
    Junk S; Cario G; Wittner N; Stanulla M; Scherer R; Schlegelberger B; Schrappe M; von Neuhoff N; Lauten M
    Klin Padiatr; 2015 May; 227(3):123-30. PubMed ID: 25985447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of glucocorticoid resistance in paediatric acute lymphoblastic leukaemia is dependent on restoring BIM expression.
    Toscan CE; Jing D; Mayoh C; Lock RB
    Br J Cancer; 2020 Jun; 122(12):1769-1781. PubMed ID: 32242100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphocyte-Specific Chromatin Accessibility Pre-determines Glucocorticoid Resistance in Acute Lymphoblastic Leukemia.
    Jing D; Huang Y; Liu X; Sia KCS; Zhang JC; Tai X; Wang M; Toscan CE; McCalmont H; Evans K; Mayoh C; Poulos RC; Span M; Mi J; Zhang C; Wong JWH; Beck D; Pimanda JE; Lock RB
    Cancer Cell; 2018 Dec; 34(6):906-921.e8. PubMed ID: 30537513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circumvention of glucocorticoid resistance in childhood leukemia.
    Haarman EG; Kaspers GJ; Pieters R; Rottier MM; Veerman AJ
    Leuk Res; 2008 Sep; 32(9):1417-23. PubMed ID: 18395253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered expression of autophagy-related genes might contribute to glucocorticoid resistance in precursor B-cell-type acute lymphoblastic leukemia.
    Sarang Z; Gyurina K; Scholtz B; Kiss C; Szegedi I
    Eur J Haematol; 2016 Nov; 97(5):453-460. PubMed ID: 26947147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia.
    Serafin V; Capuzzo G; Milani G; Minuzzo SA; Pinazza M; Bortolozzi R; Bresolin S; Porcù E; Frasson C; Indraccolo S; Basso G; Accordi B
    Blood; 2017 Dec; 130(25):2750-2761. PubMed ID: 29101238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemia.
    Samuels AL; Beesley AH; Yadav BD; Papa RA; Sutton R; Anderson D; Marshall GM; Cole CH; Kees UR; Lock RB
    Blood Cancer J; 2014 Aug; 4(8):e232. PubMed ID: 25083816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the NOD/SCID xenograft model for glucocorticoid-regulated gene expression in childhood B-cell precursor acute lymphoblastic leukemia.
    Bhadri VA; Cowley MJ; Kaplan W; Trahair TN; Lock RB
    BMC Genomics; 2011 Nov; 12():565. PubMed ID: 22093874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia.
    Vilas-Zornoza A; Agirre X; Abizanda G; Moreno C; Segura V; De Martino Rodriguez A; José-Eneriz ES; Miranda E; Martín-Subero JI; Garate L; Blanco-Prieto MJ; García de Jalón JA; Rio P; Rifón J; Cigudosa JC; Martinez-Climent JA; Román-Gómez J; Calasanz MJ; Ribera JM; Prósper F
    Leukemia; 2012 Jul; 26(7):1517-26. PubMed ID: 22307227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of cabazitaxel and plicamycin induces cell death in drug resistant B-cell acute lymphoblastic leukemia.
    Nair RR; Piktel D; Geldenhuys WJ; Gibson LF
    Leuk Res; 2018 Sep; 72():59-66. PubMed ID: 30103201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of Akt is associated with poor prognosis and chemotherapeutic resistance in pediatric B-precursor acute lymphoblastic leukemia.
    Morishita N; Tsukahara H; Chayama K; Ishida T; Washio K; Miyamura T; Yamashita N; Oda M; Morishima T
    Pediatr Blood Cancer; 2012 Jul; 59(1):83-9. PubMed ID: 22183914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells.
    Schult C; Dahlhaus M; Glass A; Fischer K; Lange S; Freund M; Junghanss C
    Anticancer Res; 2012 Feb; 32(2):463-74. PubMed ID: 22287733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of the deubiquitinase USP9X attenuates B-cell acute lymphoblastic leukemia cell survival and overcomes glucocorticoid resistance.
    Zhou M; Wang T; Lai H; Zhao X; Yu Q; Zhou J; Yang Y
    Biochem Biophys Res Commun; 2015 Apr; 459(2):333-339. PubMed ID: 25735983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia.
    Kruth KA; Fang M; Shelton DN; Abu-Halawa O; Mahling R; Yang H; Weissman JS; Loh ML; Müschen M; Tasian SK; Bassik MC; Kampmann M; Pufall MA
    Blood; 2017 Jun; 129(22):3000-3008. PubMed ID: 28424165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stability of gene expression and epigenetic profiles highlights the utility of patient-derived paediatric acute lymphoblastic leukaemia xenografts for investigating molecular mechanisms of drug resistance.
    Wong NC; Bhadri VA; Maksimovic J; Parkinson-Bates M; Ng J; Craig JM; Saffery R; Lock RB
    BMC Genomics; 2014 Jun; 15(1):416. PubMed ID: 24885906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of microRNAs in glucocorticoid‑resistant B‑cell precursor acute lymphoblastic leukemia.
    Sakurai N; Komada Y; Hanaki R; Morimoto M; Ito T; Nakato D; Hirayama M
    Oncol Rep; 2019 Aug; 42(2):708-716. PubMed ID: 31233193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxicity of cortivazol in childhood acute lymphoblastic leukemia.
    Styczynski J; Kurylak A; Wysocki M
    Anticancer Res; 2005; 25(3B):2253-8. PubMed ID: 16158972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute lymphoblastic leukemia cells treated with CpG oligodeoxynucleotides, IL-4 and CD40 ligand facilitate enhanced anti-leukemic CTL responses.
    Fabricius D; Breckerbohm L; Vollmer A; Queudeville M; Eckhoff SM; Fulda S; Strauss G; Debatin KM; Jahrsdörfer B; Meyer LH
    Leukemia; 2011 Jul; 25(7):1111-21. PubMed ID: 21527935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.